Evidence map›Paper›PMID 30055585›Full record

ArticleBMC cancer2018

Prognosis of ovarian cancer in women with type 2 diabetes using metformin and other forms of antidiabetic medication or statins: a retrospective cohort study.

Elina Urpilainen, Mikko Marttila, Ari Hautakoski, Martti Arffman, Reijo Sund, Pirjo Ilanne-Parikka, Reetta Arima, Jenni Kangaskokko, Ulla Puistola, Marianne Hinkula and 1 more

Full text read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Metformin Use and Mortality in Women with Ovarian Cancer: An Updated Meta-Analysis.International journal of clinical practice · 2022 · on this map
    Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Review
  8. Dysregulation of Cholesterol Homeostasis in Ovarian Cancer.Current oncology (Toronto, Ont.) · 2023
    Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Metformin and ovarian cancer: the evidence.Annals of translational medicine · 2020
    Review
  16. Article
  17. Wise Management of Ovarian Cancer: On the Cutting Edge.Journal of personalized medicine · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Elina UrpilainenDepartment of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Center Oulu, University of Oulu and University Hospital of Oulu, P.O. Box 23, FIN-90029, Oulu, Finland. elina.urpilainen@gmail.com.
Mikko MarttilaChildren, Adolescents and Families Unit, Department of Welfare, National Institute for Health and Welfare, P.O. Box 310, FIN-90101, Oulu, Finland.
Ari HautakoskiResearch Unit of Mathematical Sciences, University of Oulu, P.O. Box 8000, FIN-90014, Oulu, Finland.
Martti ArffmanService System Research Unit, National Institute for Health and Welfare, P.O. Box 30, FIN-00271, Helsinki, Finland.
Reijo SundCentre for Research Methods, Department of Social Research, University of Helsinki, Helsinki, Finland.
Pirjo Ilanne-ParikkaThe Diabetes Center, Finnish Diabetes Association, FIN-33680, Tampere, Finland.
Reetta ArimaDepartment of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Center Oulu, University of Oulu and University Hospital of Oulu, P.O. Box 23, FIN-90029, Oulu, Finland.
Jenni KangaskokkoMedical Research Center Oulu, University of Oulu, P.O. Box 8000, FIN-90014, Oulu, Finland.
Ulla PuistolaDepartment of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Center Oulu, University of Oulu and University Hospital of Oulu, P.O. Box 23, FIN-90029, Oulu, Finland.
Marianne HinkulaDepartment of Obstetrics and Gynecology, PEDEGO Research Unit, Medical Research Center Oulu, University of Oulu and University Hospital of Oulu, P.O. Box 23, FIN-90029, Oulu, Finland.
Esa LääräResearch Unit of Mathematical Sciences, University of Oulu, P.O. Box 8000, FIN-90014, Oulu, Finland.

Funding

Finnish Government Research Funds K77729Jane ja Aatos Erkon Säätiö T59127The Cancer Foundation of Finland T59129
6 · The paper itself

Abstract

backgroundOvarian cancer is one of the most lethal cancers and women with type 2 diabetes (T2D) have even poorer survival from it. We assessed the prognosis of ovarian cancer in women with type 2 diabetes treated with metformin, other forms of antidiabetic medication, or statins.

methodsStudy cohort consisted of women with T2D diagnosed with ovarian cancer in Finland 1998-2011. They were identified from a nationwide diabetes database (FinDM), being linked to several national registers. Patients were grouped according to their medication in the three years preceding ovarian cancer diagnosis. The Aalen-Johansen estimator was used to describe cumulative mortality from ovarian cancer and from other causes in different medication groups. Mortality rates were analysed by Cox models, and adjusted hazard ratios (HR) with 95% confidence intervals (95% CIs) were estimated in relation to the use of different forms of medication. Main outcome measures were death from ovarian cancer and death from other causes.

resultsDuring the accrual period 421 newly diagnosed ovarian cancers were identified in the FinDM database. No evidence was found for any differences in mortality from ovarian cancer or other causes between different antidiabetic medication groups. Pre-diagnostic use of statins was observed to be associated with decreased mortality from ovarian cancer compared with no such use (HR 0.72, 95% CI 0.56-0.93).

conclusionsOur findings are inconclusive as regards the association between metformin and ovarian cancer survival. However, some evidence was found for improved prognosis of ovarian cancer with pre-diagnostic statin use, requiring cautious interpretation, though.

Indexed as

Diabetes Mellitus, Type 2Ovarian NeoplasmsAdultAgedAged, 80 and overFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMetforminMiddle AgedPrognosisRetrospective StudiesHydroxymethylglutaryl-CoA Reductase InhibitorsHypoglycemic AgentsMetforminAntidiabetic medicationCancer prognosisCancer survivalMetforminOvarian cancerStatinsType 2 diabetes

Identifiers

PMID30055585
PMCPMC6064082

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.